Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vanguard Value Index Fund ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vanguard Value Index Fund ETF trades at $221.23 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 53.8× Travere Therapeutics Inc. Common Stock's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| TVTX | VTV | |
|---|---|---|
Market Cap | $4.88B | $262.40B |
Volume | 1,668,577 | 1,774,364 |
Sector | Health | — |
52-Week High | $67.52 | $227.51 |
52-Week Low | $26.79 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VTV trades at $221.14, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI levels. The ETF offers a 2.3% dividend yield and has attracted institutional inflows, with recent news highlighting its outperformance versus growth funds in 2026. Value stocks are gaining favor amid market rotation away from tech concentration.
Outlook remains positive given value's momentum and institutional interest, though risks include prolonged underperformance versus growth and fee-related long-term tracking differences. The ETF provides stable income and diversification but faces competition from broader market funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
